NEW BRUNSWICK, N.J. / Jul 29, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the 2024 Wells Fargo Healthcare Conference on Thursday, September 5th, at the Encore Boston Harbor, Evertte, MA. Tim Schmid, Executive Vice President, WorldWide Chairman, MedTech will represent the Company in a session scheduled at 11:00 am (Eastern Time).
This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.
The audio webcast replay will be available approximately 48-hrs after the webcast.
| Last Trade: | US$190.85 |
| Daily Change: | -0.05 -0.03 |
| Daily Volume: | 12,681,496 |
| Market Cap: | US$459.950B |
October 14, 2025 October 10, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
